VI 16832 is a broad-spectrum Type I kinase inhibitor used for comparative expression analysis of protein kinases across cancer cell lines, enabling the quantification of relative kinase abundance. VI 16832 has been employed to analyze over 170 protein kinases in multiple SILAC-encoded cancer cell lines, providing a versatile tool for kinase signaling studies and pharmacological research.

VI 16832 is a broad-spectrum type I kinase inhibitor [1]. Phosphoproteomic analysis of VI 16832-enriched fractions in MV4-11, HCT116, or 435S cells identified over 8,500 phosphopeptides. These phosphopeptides correspond to 212 distinct members of the protein kinase superfamily, forming nearly 1,700 different phosphopeptide species. Analysis of VI 16832-bound retained proteins across the three cancer cell lines significantly increased the total number of identified phosphorylation sites on protein kinases. When the sum of all phosphopeptide intensities was used as a measure of VI 16832-enriched protein quantity, it was found that over 80% of these proteins originated from protein kinases [2].